Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, serum-separating tubes, blood transfusion bags, and dialysis equipment.

The global Novel Oral AntiCoagulants (NOAC) market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.

Market competition is intense. Sanofi, Bristol-Myers Squibb, Bayer, Johnson & Johnson, Genentech (Roche) and Boehringer Ingelheim etc. are the leaders of the industry, with about 64% market shares.

North America is the largest consumption place, with a consumption market share nearly 39%. Following North America, Europe is the second largest consumption place with the consumption market share of 26%.

This report aims to provide a comprehensive presentation of the global market for Novel Oral AntiCoagulants (NOAC), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Oral AntiCoagulants (NOAC).

The Novel Oral AntiCoagulants (NOAC) market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Novel Oral AntiCoagulants (NOAC) market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Novel Oral AntiCoagulants (NOAC) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.

1.1 Product Overview and Scope of Novel Oral AntiCoagulants (NOAC)

1.2 Novel Oral AntiCoagulants (NOAC) Segment by Type

1.2.1 Global Novel Oral AntiCoagulants (NOAC) Market Value Comparison by Type (2023-2029)

1.2.2 Direct Thrombin Inhibitors

1.2.3 Direct Factor Xa Inhibitors

1.3 Novel Oral AntiCoagulants (NOAC) Segment by Application

1.3.1 Global Novel Oral AntiCoagulants (NOAC) Market Value by Application: (2023-2029)

1.3.2 Deep Vein Thrombosis (DVT)

1.3.3 Pulmonary Embolism

1.3.4 Acute Coronary Syndrome

1.3.5 Hemodialysis

1.3.6 Others

1.4 Global Novel Oral AntiCoagulants (NOAC) Market Size Estimates and Forecasts

1.4.1 Global Novel Oral AntiCoagulants (NOAC) Revenue 2018-2029

1.4.2 Global Novel Oral AntiCoagulants (NOAC) Sales 2018-2029

1.4.3 Global Novel Oral AntiCoagulants (NOAC) Market Average Price (2018-2029)

1.5 Assumptions and Limitations

2.1 Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Manufacturers (2018-2023)

2.2 Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Manufacturers (2018-2023)

2.3 Global Novel Oral AntiCoagulants (NOAC) Average Price by Manufacturers (2018-2023)

2.4 Global Novel Oral AntiCoagulants (NOAC) Industry Ranking 2021 VS 2022 VS 2023

2.5 Global Key Manufacturers of Novel Oral AntiCoagulants (NOAC), Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Novel Oral AntiCoagulants (NOAC), Product Type & Application

2.7 Novel Oral AntiCoagulants (NOAC) Market Competitive Situation and Trends

2.7.1 Novel Oral AntiCoagulants (NOAC) Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Novel Oral AntiCoagulants (NOAC) Players Market Share by Revenue

2.7.3 Global Novel Oral AntiCoagulants (NOAC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3.1 Global Novel Oral AntiCoagulants (NOAC) Market Size by Region: 2018 Versus 2022 Versus 2029

3.2 Global Novel Oral AntiCoagulants (NOAC) Global Novel Oral AntiCoagulants (NOAC) Sales by Region: 2018-2029

3.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Region: 2018-2023

3.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Region: 2024-2029

3.3 Global Novel Oral AntiCoagulants (NOAC) Global Novel Oral AntiCoagulants (NOAC) Revenue by Region: 2018-2029

3.3.1 Global Novel Oral AntiCoagulants (NOAC) Revenue by Region: 2018-2023

3.3.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Region: 2024-2029

3.4 North America Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Country

3.4.1 North America Novel Oral AntiCoagulants (NOAC) Market Size by Country: 2018 VS 2022 VS 2029

3.4.2 North America Novel Oral AntiCoagulants (NOAC) Sales by Country (2018-2029)

3.4.3 North America Novel Oral AntiCoagulants (NOAC) Revenue by Country (2018-2029)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Country

3.5.1 Europe Novel Oral AntiCoagulants (NOAC) Market Size by Country: 2018 VS 2022 VS 2029

3.5.2 Europe Novel Oral AntiCoagulants (NOAC) Sales by Country (2018-2029)

3.5.3 Europe Novel Oral AntiCoagulants (NOAC) Revenue by Country (2018-2029)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Country

3.6.1 Asia Pacific Novel Oral AntiCoagulants (NOAC) Market Size by Country: 2018 VS 2022 VS 2029

3.6.2 Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales by Country (2018-2029)

3.6.3 Asia Pacific Novel Oral AntiCoagulants (NOAC) Revenue by Country (2018-2029)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Country

3.7.1 Latin America Novel Oral AntiCoagulants (NOAC) Market Size by Country: 2018 VS 2022 VS 2029

3.7.2 Latin America Novel Oral AntiCoagulants (NOAC) Sales by Country (2018-2029)

3.7.3 Latin America Novel Oral AntiCoagulants (NOAC) Revenue by Country (2018-2029)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Country

3.8.1 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size by Country: 2018 VS 2022 VS 2029

3.8.2 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Country (2018-2029)

3.8.3 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Revenue by Country (2018-2029)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2018-2029)

4.1.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2018-2023)

4.1.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2024-2029)

4.1.3 Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2018-2029)

4.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Type (2018-2029)

4.2.1 Global Novel Oral AntiCoagulants (NOAC) Revenue by Type (2018-2023)

4.2.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Type (2024-2029)

4.2.3 Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type (2018-2029)

4.3 Global Novel Oral AntiCoagulants (NOAC) Price by Type (2018-2029)

5.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2018-2029)

5.1.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2018-2023)

5.1.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2024-2029)

5.1.3 Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2018-2029)

5.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Application (2018-2029)

5.2.1 Global Novel Oral AntiCoagulants (NOAC) Revenue by Application (2018-2023)

5.2.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Application (2024-2029)

5.2.3 Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Application (2018-2029)

5.3 Global Novel Oral AntiCoagulants (NOAC) Price by Application (2018-2029)

6.1 Johnson & Johnson

6.1.1 Johnson & Johnson Corporation Information

6.1.2 Johnson & Johnson Description and Business Overview

6.1.3 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.1.4 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.1.5 Johnson & Johnson Recent Developments/Updates

6.2 Bristol-Myers Squibb

6.2.1 Bristol-Myers Squibb Corporation Information

6.2.2 Bristol-Myers Squibb Description and Business Overview

6.2.3 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.2.4 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.2.5 Bristol-Myers Squibb Recent Developments/Updates

6.3 Boehringer Ingelheim

6.3.1 Boehringer Ingelheim Corporation Information

6.3.2 Boehringer Ingelheim Description and Business Overview

6.3.3 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.3.4 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.3.5 Boehringer Ingelheim Recent Developments/Updates

6.4 Sanofi

6.4.1 Sanofi Corporation Information

6.4.2 Sanofi Description and Business Overview

6.4.3 Sanofi Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.4.4 Sanofi Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.4.5 Sanofi Recent Developments/Updates

6.5 Daiichi Sankyo

6.5.1 Daiichi Sankyo Corporation Information

6.5.2 Daiichi Sankyo Description and Business Overview

6.5.3 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.5.4 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.5.5 Daiichi Sankyo Recent Developments/Updates

6.6 Armatheon

6.6.1 Armatheon Corporation Information

6.6.2 Armatheon Description and Business Overview

6.6.3 Armatheon Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.6.4 Armatheon Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.6.5 Armatheon Recent Developments/Updates

6.7 Aspen

6.6.1 Aspen Corporation Information

6.6.2 Aspen Description and Business Overview

6.6.3 Aspen Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.4.4 Aspen Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.7.5 Aspen Recent Developments/Updates

6.8 AstraZeneca

6.8.1 AstraZeneca Corporation Information

6.8.2 AstraZeneca Description and Business Overview

6.8.3 AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.8.4 AstraZeneca Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.8.5 AstraZeneca Recent Developments/Updates

6.9 Bayer

6.9.1 Bayer Corporation Information

6.9.2 Bayer Description and Business Overview

6.9.3 Bayer Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.9.4 Bayer Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.9.5 Bayer Recent Developments/Updates

6.10 Cellceutix

6.10.1 Cellceutix Corporation Information

6.10.2 Cellceutix Description and Business Overview

6.10.3 Cellceutix Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.10.4 Cellceutix Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.10.5 Cellceutix Recent Developments/Updates

6.11 Cosmo Pharmaceuticals

6.11.1 Cosmo Pharmaceuticals Corporation Information

6.11.2 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Description and Business Overview

6.11.3 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.11.4 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.11.5 Cosmo Pharmaceuticals Recent Developments/Updates

6.12 CSL Behring

6.12.1 CSL Behring Corporation Information

6.12.2 CSL Behring Novel Oral AntiCoagulants (NOAC) Description and Business Overview

6.12.3 CSL Behring Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.12.4 CSL Behring Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.12.5 CSL Behring Recent Developments/Updates

6.13 Eisai

6.13.1 Eisai Corporation Information

6.13.2 Eisai Novel Oral AntiCoagulants (NOAC) Description and Business Overview

6.13.3 Eisai Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.13.4 Eisai Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.13.5 Eisai Recent Developments/Updates

6.14 GSK

6.14.1 GSK Corporation Information

6.14.2 GSK Novel Oral AntiCoagulants (NOAC) Description and Business Overview

6.14.3 GSK Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.14.4 GSK Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.14.5 GSK Recent Developments/Updates

6.15 Marathon Pharmaceuticals

6.15.1 Marathon Pharmaceuticals Corporation Information

6.15.2 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Description and Business Overview

6.15.3 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.15.4 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.15.5 Marathon Pharmaceuticals Recent Developments/Updates

6.16 Ockham Biotech

6.16.1 Ockham Biotech Corporation Information

6.16.2 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Description and Business Overview

6.16.3 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.16.4 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.16.5 Ockham Biotech Recent Developments/Updates

6.17 Perosphere

6.17.1 Perosphere Corporation Information

6.17.2 Perosphere Novel Oral AntiCoagulants (NOAC) Description and Business Overview

6.17.3 Perosphere Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2018-2023)

6.17.4 Perosphere Novel Oral AntiCoagulants (NOAC) Product Portfolio

6.17.5 Perosphere Recent Developments/Updates

7.1 Novel Oral AntiCoagulants (NOAC) Industry Chain Analysis

7.2 Novel Oral AntiCoagulants (NOAC) Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Novel Oral AntiCoagulants (NOAC) Production Mode & Process

7.4 Novel Oral AntiCoagulants (NOAC) Sales and Marketing

7.4.1 Novel Oral AntiCoagulants (NOAC) Sales Channels

7.4.2 Novel Oral AntiCoagulants (NOAC) Distributors

7.5 Novel Oral AntiCoagulants (NOAC) Customers

8.1 Novel Oral AntiCoagulants (NOAC) Industry Trends

8.2 Novel Oral AntiCoagulants (NOAC) Market Drivers

8.3 Novel Oral AntiCoagulants (NOAC) Market Challenges

8.4 Novel Oral AntiCoagulants (NOAC) Market Restraints

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

List of Tables

    Table 1. Global Novel Oral AntiCoagulants (NOAC) Market Value Comparison by Type (2023-2029) & (US$ Million)

    Table 2. Global Novel Oral AntiCoagulants (NOAC) Market Value Comparison by Application (2023-2029) & (US$ Million)

    Table 3. Global Novel Oral AntiCoagulants (NOAC) Market Competitive Situation by Manufacturers in 2022

    Table 4. Global Novel Oral AntiCoagulants (NOAC) Sales (K Pcs) of Key Manufacturers (2018-2023)

    Table 5. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Manufacturers (2018-2023)

    Table 6. Global Novel Oral AntiCoagulants (NOAC) Revenue (US$ Million) by Manufacturers (2018-2023)

    Table 7. Global Novel Oral AntiCoagulants (NOAC) Revenue Share by Manufacturers (2018-2023)

    Table 8. Global Market Novel Oral AntiCoagulants (NOAC) Average Price (USD/Pcs) of Key Manufacturers (2018-2023)

    Table 9. Global Key Players of Novel Oral AntiCoagulants (NOAC), Industry Ranking, 2021 VS 2022 VS 2023

    Table 10. Global Key Manufacturers of Novel Oral AntiCoagulants (NOAC), Manufacturing Sites & Headquarters

    Table 11. Global Key Manufacturers of Novel Oral AntiCoagulants (NOAC), Product Type & Application

    Table 12. Global Key Manufacturers of Novel Oral AntiCoagulants (NOAC), Date of Enter into This Industry

    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

    Table 14. Global Novel Oral AntiCoagulants (NOAC) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Oral AntiCoagulants (NOAC) as of 2022)

    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

    Table 16. Global Novel Oral AntiCoagulants (NOAC) Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 17. Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2018-2023) & (K Pcs)

    Table 18. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Region (2018-2023)

    Table 19. Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2024-2029) & (K Pcs)

    Table 20. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Region (2024-2029)

    Table 21. Global Novel Oral AntiCoagulants (NOAC) Revenue by Region (2018-2023) & (US$ Million)

    Table 22. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region (2018-2023)

    Table 23. Global Novel Oral AntiCoagulants (NOAC) Revenue by Region (2024-2029) & (US$ Million)

    Table 24. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region (2024-2029)

    Table 25. North America Novel Oral AntiCoagulants (NOAC) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 26. North America Novel Oral AntiCoagulants (NOAC) Sales by Country (2018-2023) & (K Pcs)

    Table 27. North America Novel Oral AntiCoagulants (NOAC) Sales by Country (2024-2029) & (K Pcs)

    Table 28. North America Novel Oral AntiCoagulants (NOAC) Revenue by Country (2018-2023) & (US$ Million)

    Table 29. North America Novel Oral AntiCoagulants (NOAC) Revenue by Country (2024-2029) & (US$ Million)

    Table 30. Europe Novel Oral AntiCoagulants (NOAC) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 31. Europe Novel Oral AntiCoagulants (NOAC) Sales by Country (2018-2023) & (K Pcs)

    Table 32. Europe Novel Oral AntiCoagulants (NOAC) Sales by Country (2024-2029) & (K Pcs)

    Table 33. Europe Novel Oral AntiCoagulants (NOAC) Revenue by Country (2018-2023) & (US$ Million)

    Table 34. Europe Novel Oral AntiCoagulants (NOAC) Revenue by Country (2024-2029) & (US$ Million)

    Table 35. Asia Pacific Novel Oral AntiCoagulants (NOAC) Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)

    Table 36. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales by Region (2018-2023) & (K Pcs)

    Table 37. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales by Region (2024-2029) & (K Pcs)

    Table 38. Asia Pacific Novel Oral AntiCoagulants (NOAC) Revenue by Region (2018-2023) & (US$ Million)

    Table 39. Asia Pacific Novel Oral AntiCoagulants (NOAC) Revenue by Region (2024-2029) & (US$ Million)

    Table 40. Latin America Novel Oral AntiCoagulants (NOAC) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 41. Latin America Novel Oral AntiCoagulants (NOAC) Sales by Country (2018-2023) & (K Pcs)

    Table 42. Latin America Novel Oral AntiCoagulants (NOAC) Sales by Country (2024-2029) & (K Pcs)

    Table 43. Latin America Novel Oral AntiCoagulants (NOAC) Revenue by Country (2018-2023) & (US$ Million)

    Table 44. Latin America Novel Oral AntiCoagulants (NOAC) Revenue by Country (2024-2029) & (US$ Million)

    Table 45. Middle East & Africa Novel Oral AntiCoagulants (NOAC) Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 46. Middle East & Africa Novel Oral AntiCoagulants (NOAC) Sales by Country (2018-2023) & (K Pcs)

    Table 47. Middle East & Africa Novel Oral AntiCoagulants (NOAC) Sales by Country (2024-2029) & (K Pcs)

    Table 48. Middle East & Africa Novel Oral AntiCoagulants (NOAC) Revenue by Country (2018-2023) & (US$ Million)

    Table 49. Middle East & Africa Novel Oral AntiCoagulants (NOAC) Revenue by Country (2024-2029) & (US$ Million)

    Table 50. Global Novel Oral AntiCoagulants (NOAC) Sales (K Pcs) by Type (2018-2023)

    Table 51. Global Novel Oral AntiCoagulants (NOAC) Sales (K Pcs) by Type (2024-2029)

    Table 52. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2018-2023)

    Table 53. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2024-2029)

    Table 54. Global Novel Oral AntiCoagulants (NOAC) Revenue (US$ Million) by Type (2018-2023)

    Table 55. Global Novel Oral AntiCoagulants (NOAC) Revenue (US$ Million) by Type (2024-2029)

    Table 56. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type (2018-2023)

    Table 57. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type (2024-2029)

    Table 58. Global Novel Oral AntiCoagulants (NOAC) Price (USD/Pcs) by Type (2018-2023)

    Table 59. Global Novel Oral AntiCoagulants (NOAC) Price (USD/Pcs) by Type (2024-2029)

    Table 60. Global Novel Oral AntiCoagulants (NOAC) Sales (K Pcs) by Application (2018-2023)

    Table 61. Global Novel Oral AntiCoagulants (NOAC) Sales (K Pcs) by Application (2024-2029)

    Table 62. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2018-2023)

    Table 63. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2024-2029)

    Table 64. Global Novel Oral AntiCoagulants (NOAC) Revenue (US$ Million) by Application (2018-2023)

    Table 65. Global Novel Oral AntiCoagulants (NOAC) Revenue (US$ Million) by Application (2024-2029)

    Table 66. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Application (2018-2023)

    Table 67. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Application (2024-2029)

    Table 68. Global Novel Oral AntiCoagulants (NOAC) Price (USD/Pcs) by Application (2018-2023)

    Table 69. Global Novel Oral AntiCoagulants (NOAC) Price (USD/Pcs) by Application (2024-2029)

    Table 70. Johnson & Johnson Corporation Information

    Table 71. Johnson & Johnson Description and Business Overview

    Table 72. Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 73. Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Product

    Table 74. Johnson & Johnson Recent Developments/Updates

    Table 75. Bristol-Myers Squibb Corporation Information

    Table 76. Bristol-Myers Squibb Description and Business Overview

    Table 77. Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 78. Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Product

    Table 79. Bristol-Myers Squibb Recent Developments/Updates

    Table 80. Boehringer Ingelheim Corporation Information

    Table 81. Boehringer Ingelheim Description and Business Overview

    Table 82. Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 83. Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Product

    Table 84. Boehringer Ingelheim Recent Developments/Updates

    Table 85. Sanofi Corporation Information

    Table 86. Sanofi Description and Business Overview

    Table 87. Sanofi Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 88. Sanofi Novel Oral AntiCoagulants (NOAC) Product

    Table 89. Sanofi Recent Developments/Updates

    Table 90. Daiichi Sankyo Corporation Information

    Table 91. Daiichi Sankyo Description and Business Overview

    Table 92. Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 93. Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Product

    Table 94. Daiichi Sankyo Recent Developments/Updates

    Table 95. Armatheon Corporation Information

    Table 96. Armatheon Description and Business Overview

    Table 97. Armatheon Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 98. Armatheon Novel Oral AntiCoagulants (NOAC) Product

    Table 99. Armatheon Recent Developments/Updates

    Table 100. Aspen Corporation Information

    Table 101. Aspen Description and Business Overview

    Table 102. Aspen Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 103. Aspen Novel Oral AntiCoagulants (NOAC) Product

    Table 104. Aspen Recent Developments/Updates

    Table 105. AstraZeneca Corporation Information

    Table 106. AstraZeneca Description and Business Overview

    Table 107. AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 108. AstraZeneca Novel Oral AntiCoagulants (NOAC) Product

    Table 109. AstraZeneca Recent Developments/Updates

    Table 110. Bayer Corporation Information

    Table 111. Bayer Description and Business Overview

    Table 112. Bayer Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 113. Bayer Novel Oral AntiCoagulants (NOAC) Product

    Table 114. Bayer Recent Developments/Updates

    Table 115. Cellceutix Corporation Information

    Table 116. Cellceutix Description and Business Overview

    Table 117. Cellceutix Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 118. Cellceutix Novel Oral AntiCoagulants (NOAC) Product

    Table 119. Cellceutix Recent Developments/Updates

    Table 120. Cosmo Pharmaceuticals Corporation Information

    Table 121. Cosmo Pharmaceuticals Description and Business Overview

    Table 122. Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 123. Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product

    Table 124. Cosmo Pharmaceuticals Recent Developments/Updates

    Table 125. CSL Behring Corporation Information

    Table 126. CSL Behring Description and Business Overview

    Table 127. CSL Behring Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 128. CSL Behring Novel Oral AntiCoagulants (NOAC) Product

    Table 129. CSL Behring Recent Developments/Updates

    Table 130. Eisai Corporation Information

    Table 131. Eisai Description and Business Overview

    Table 132. Eisai Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 133. Eisai Novel Oral AntiCoagulants (NOAC) Product

    Table 134. Eisai Recent Developments/Updates

    Table 135. GSK Corporation Information

    Table 136. GSK Description and Business Overview

    Table 137. GSK Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 138. GSK Novel Oral AntiCoagulants (NOAC) Product

    Table 139. GSK Recent Developments/Updates

    Table 140. Marathon Pharmaceuticals Corporation Information

    Table 141. Marathon Pharmaceuticals Description and Business Overview

    Table 142. Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 143. Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product

    Table 144. Marathon Pharmaceuticals Recent Developments/Updates

    Table 145. Ockham Biotech Corporation Information

    Table 146. Ockham Biotech Description and Business Overview

    Table 147. Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 148. Ockham Biotech Novel Oral AntiCoagulants (NOAC) Product

    Table 149. Ockham Biotech Recent Developments/Updates

    Table 150. Perosphere Corporation Information

    Table 151. Perosphere Description and Business Overview

    Table 152. Perosphere Novel Oral AntiCoagulants (NOAC) Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023)

    Table 153. Perosphere Novel Oral AntiCoagulants (NOAC) Product

    Table 154. Perosphere Recent Developments/Updates

    Table 155. Key Raw Materials Lists

    Table 156. Raw Materials Key Suppliers Lists

    Table 157. Novel Oral AntiCoagulants (NOAC) Distributors List

    Table 158. Novel Oral AntiCoagulants (NOAC) Customers List

    Table 159. Novel Oral AntiCoagulants (NOAC) Market Trends

    Table 160. Novel Oral AntiCoagulants (NOAC) Market Drivers

    Table 161. Novel Oral AntiCoagulants (NOAC) Market Challenges

    Table 162. Novel Oral AntiCoagulants (NOAC) Market Restraints

    Table 163. Research Programs/Design for This Report

    Table 164. Key Data Information from Secondary Sources

    Table 165. Key Data Information from Primary Sources

List of Figures

    Figure 1. Product Picture of Novel Oral AntiCoagulants (NOAC)

    Figure 2. Global Novel Oral AntiCoagulants (NOAC) Market Value Comparison by Type (2023-2029) & (US$ Million)

    Figure 3. Global Novel Oral AntiCoagulants (NOAC) Market Share by Type in 2022 & 2029

    Figure 4. Direct Thrombin Inhibitors Product Picture

    Figure 5. Direct Factor Xa Inhibitors Product Picture

    Figure 6. Global Novel Oral AntiCoagulants (NOAC) Market Value Comparison by Application (2023-2029) & (US$ Million)

    Figure 7. Global Novel Oral AntiCoagulants (NOAC) Market Share by Application in 2022 & 2029

    Figure 8. Deep Vein Thrombosis (DVT)

    Figure 9. Pulmonary Embolism

    Figure 10. Acute Coronary Syndrome

    Figure 11. Hemodialysis

    Figure 12. Others

    Figure 13. Global Novel Oral AntiCoagulants (NOAC) Revenue, (US$ Million), 2018 VS 2022 VS 2029

    Figure 14. Global Novel Oral AntiCoagulants (NOAC) Market Size (2018-2029) & (US$ Million)

    Figure 15. Global Novel Oral AntiCoagulants (NOAC) Sales (2018-2029) & (K Pcs)

    Figure 16. Global Novel Oral AntiCoagulants (NOAC) Average Price (USD/Pcs) & (2018-2029)

    Figure 17. Novel Oral AntiCoagulants (NOAC) Report Years Considered

    Figure 18. Novel Oral AntiCoagulants (NOAC) Sales Share by Manufacturers in 2022

    Figure 19. Global Novel Oral AntiCoagulants (NOAC) Revenue Share by Manufacturers in 2022

    Figure 20. The Global 5 and 10 Largest Novel Oral AntiCoagulants (NOAC) Players: Market Share by Revenue in 2022

    Figure 21. Novel Oral AntiCoagulants (NOAC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022

    Figure 22. Global Novel Oral AntiCoagulants (NOAC) Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Figure 23. North America Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2018-2029)

    Figure 24. North America Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Country (2018-2029)

    Figure 25. U.S. Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 26. Canada Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 27. Europe Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2018-2029)

    Figure 28. Europe Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Country (2018-2029)

    Figure 29. Germany Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 30. France Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 31. U.K. Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 32. Italy Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 33. Russia Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 34. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales Market Share by Region (2018-2029)

    Figure 35. Asia Pacific Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region (2018-2029)

    Figure 36. China Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 37. Japan Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 38. South Korea Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 39. India Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 40. Australia Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 41. China Taiwan Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 42. Indonesia Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 43. Thailand Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 44. Malaysia Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 45. Latin America Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2018-2029)

    Figure 46. Latin America Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Country (2018-2029)

    Figure 47. Mexico Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 48. Brazil Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 49. Argentina Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 50. Middle East & Africa Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2018-2029)

    Figure 51. Middle East & Africa Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Country (2018-2029)

    Figure 52. Turkey Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 53. Saudi Arabia Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 54. UAE Novel Oral AntiCoagulants (NOAC) Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 55. Global Sales Market Share of Novel Oral AntiCoagulants (NOAC) by Type (2018-2029)

    Figure 56. Global Revenue Market Share of Novel Oral AntiCoagulants (NOAC) by Type (2018-2029)

    Figure 57. Global Novel Oral AntiCoagulants (NOAC) Price (USD/Pcs) by Type (2018-2029)

    Figure 58. Global Sales Market Share of Novel Oral AntiCoagulants (NOAC) by Application (2018-2029)

    Figure 59. Global Revenue Market Share of Novel Oral AntiCoagulants (NOAC) by Application (2018-2029)

    Figure 60. Global Novel Oral AntiCoagulants (NOAC) Price (USD/Pcs) by Application (2018-2029)

    Figure 61. Novel Oral AntiCoagulants (NOAC) Value Chain

    Figure 62. Novel Oral AntiCoagulants (NOAC) Production Process

    Figure 63. Channels of Distribution (Direct Vs Distribution)

    Figure 64. Distributors Profiles

    Figure 65. Bottom-up and Top-down Approaches for This Report

    Figure 66. Data Triangulation

    Figure 67. Key Executives Interviewed